The Crohn’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.
DelveInsight’s “Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Crohn’s Disease, historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Crohn’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn’s Disease Market Forecast
Some of the key facts of the Crohn’s Disease Market Report:
-
The Crohn’s Disease market size was valued approximately USD 7,801 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In October 2023, The US FDA has approved WEZLENA (ustekinumab-auub) as a biosimilar and interchangeable alternative to STELARA for treating various inflammatory diseases.
-
In October 2023, Eli Lilly reported that mirikizumab achieved the coprimary and all major secondary endpoints in comparison to a placebo in VIVID-1, a Phase III study assessing the safety and effectiveness of mirikizumab for treating adults with moderately to severely active Crohn’s disease.
-
In May 2023, The US FDA approved RINVOQ (upadacitinib) as the first oral medication for moderate to severe Crohn’s Disease.
-
The number of diagnosed prevalent cases of Crohn’s Disease in Japan was approximately 55,000 in 2023. It is anticipated that these cases will rise over the forecast period spanning from 2024 to 2034.
-
In the United States, the majority of individuals with Crohn’s Disease were in the 18–44 year age bracket, totaling around 616,000 cases in 2023. It is expected that these cases will continue to rise by the year 2034.
-
Among the European Union countries (EU4) and the United Kingdom, Spain had the fewest diagnosed prevalent cases of Crohn’s Disease, with approximately 85,000 cases in 2023.
-
In 2023, around 432,000 cases were managed within the mild patient pool in the United States.
-
Key Crohn’s Disease Companies: Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others
-
Key Crohn’s Disease Therapies: Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others
-
In 2023, there were about 432,000 cases classified as mild, and approximately 708,000 cases classified as moderate to severe (including those that transitioned from mild to moderate to severe) in the United States.
-
The Crohn’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.
Crohn’s Disease Overview
Crohn’s disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the digestive tract. It can affect any part of the gastrointestinal (GI) tract, from the mouth to the anus, but most commonly affects the small intestine and the beginning of the large intestine (colon). Crohn’s disease is a lifelong condition with periods of active inflammation (flare-ups) alternating with periods of remission.
Get a Free sample for the Crohn’s Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/crohns-disease-cd-market
Crohn’s Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Crohn’s Disease Epidemiology Segmentation:
The Crohn’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Crohn’s Disease
-
Prevalent Cases of Crohn’s Disease by severity
-
Gender-specific Prevalence of Crohn’s Disease
-
Diagnosed Cases of Episodic and Chronic Crohn’s Disease
Download the report to understand which factors are driving Crohn’s Disease epidemiology trends @ Crohn’s Disease Epidemiology Forecast
Crohn’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched during the study period. The analysis covers Crohn’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Crohn’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Crohn’s Disease Therapies and Key Companies
-
Mirikizumab: Eli Lilly and Company
-
RHB-104: RedHill Biopharma
-
ZEPOSIA (ozanimod): Bristol Myers Squibb
-
budesonide: Dr. Falk Pharma GmbH
-
Guselkumab: Janssen-Cilag Ltd.
-
Risankizumab SC: AbbVie
-
E6011: EA Pharma Co., Ltd.
-
Infliximab: Erasmus Medical Center
-
CDPATH™: Takeda
-
Etrasimod: Pfizer
-
PRV-6527: Provention Bio, Inc.
-
MT-1303: Mitsubishi Tanabe Pharma Corporation
-
E6011: EA Pharma
Discover more about therapies set to grab major Crohn’s Disease market share @ Crohn’s Disease Treatment Landscape
Crohn’s Disease Market Strengths
-
Certain initiatives have been taken by private and government organizations to raise awareness about the disease.
-
Newer, innovative treatments such as JAK inhibitors and immune modulators are being developed. Targeted therapies (mainly biologics) penetration rate in case of moderate to severe Crohn’s Disease patients is expected to be more in future owing to availability of more products with better clinical profile and patient convenient route of administration.
Crohn’s Disease Market Opportunities
-
Drugs with similar efficacy but better safety profile and patient convenient route of administration are expected to have a significant impact on the Crohn’s Disease market dynamics.
-
The Crohn’s Disease has complex pathophysiology, including genomes and immune responses, variable clinical manifestations and disease courses, stepwise treatment options, many clinical parameters for monitoring, and unpredictable complications
Scope of the Crohn’s Disease Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Crohn’s Disease Companies: Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others
-
Key Crohn’s Disease Therapies: Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others
-
Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies
-
Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Crohn’s Disease Unmet Needs, KOL’s views, Analyst’s views, Crohn’s Disease Market Access and Reimbursement
To know more about Crohn’s Disease companies working in the treatment market, visit @ Crohn’s Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Crohn’s Disease Market Report Introduction
2. Executive Summary for Crohn’s Disease
3. SWOT analysis of Crohn’s Disease
4. Crohn’s Disease Patient Share (%) Overview at a Glance
5. Crohn’s Disease Market Overview at a Glance
6. Crohn’s Disease Disease Background and Overview
7. Crohn’s Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Crohn’s Disease
9. Crohn’s Disease Current Treatment and Medical Practices
10. Crohn’s Disease Unmet Needs
11. Crohn’s Disease Emerging Therapies
12. Crohn’s Disease Market Outlook
13. Country-Wise Crohn’s Disease Market Analysis (2019–2032)
14. Crohn’s Disease Market Access and Reimbursement of Therapies
15. Crohn’s Disease Market Drivers
16. Crohn’s Disease Market Barriers
17. Crohn’s Disease Appendix
18. Crohn’s Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/